Pharma Stocks Brace for Turbulence as Trump Unveils Steep Tariff Plan on Generic Drugs from 2028

Pharma Stocks Brace for Turbulence as Trump Unveils Steep Tariff Plan on Generic Drugs from 2028​

Shares of Sun Pharma, Cipla, Dr Reddy's Laboratories, Lupin, Aurobindo Pharma, and other Indian pharmaceutical companies are expected to face significant scrutiny following a major announcement by US President Donald Trump. The President unveiled a phased tariff structure targeting generic medicines imported into the United States, setting up a prolonged period of temporary relief followed by dramatically increased duties.

The move has put the entire segment under intense focus, especially as these firms rely heavily on the crucial US generics market. Generic medicines account for more than 90% of all prescriptions dispensed in the USA, making them a vital economic artery for Indian drugmakers.

Understanding Trump's Phased Tariff Structure​

In a post made on Truth Social, President Trump detailed the new import tariff plan. He confirmed that generic drugs entering the US will face no tariffs for a two-year period. This initial reprieve is followed by an escalating tariff structure. The duties are set to rise sharply to 100% starting August 1, 2028, and then increase further to 200% by August 1, 2029.

This proposal marks a shift in the US trade policy framework compared to previous measures. Earlier tariffs focused on branded and patented drugs, while generic medicines were specifically excluded from those initial punitive actions. The administration is now targeting this massive segment of the drug supply chain.

Strategic Mandate: Driving Localization in Pharmaceuticals​

The entire initiative is framed as part of a broader push by the Trump administration. This policy aims to encourage major pharmaceutical companies to fundamentally shift their manufacturing and related infrastructure within the United States. Punitive duties are set up for those who do not localize their production processes during the transitional period.

The announcement complements the existing most-favoured-nation drug pricing policy, which seeks to align US medicine prices with standards in other developed economies. While this new tariff structure targets generic medicines, the protection of patented and innovative medicines through previous agreements remains unchanged.

Market Positioning: How Indian Pharma Companies Are Affected​

This development offers a short period of respite to Indian pharmaceutical exporters who generate substantial revenue from the US generic drug market. The two-year tariff-free window provides these companies time to reassess their supply chains and strategic investment blueprints.

However, the proposed 100% and eventual 200% tariffs could fundamentally alter the economics of supplying generics to the US for firms lacking a strong local manufacturing footprint. Industry executives note that while India's cost-efficient ecosystem remains globally competitive, these prolonged tariff barriers force critical decisions.

Corporate Vulnerability and Readiness Assessment​

Different Indian pharma companies are positioned across a spectrum of risk and advantage based on their existing infrastructure in America. Aurobindo Pharma is cited as having a substantial local manufacturing presence within the US. Dr Reddy's, Cipla, Lupin, and Zydus Lifesciences also maintain some manufacturing capacity footprint there.

Other key players include Alkem Laboratories and Torrent Pharmaceuticals, which are largely dependent on Indian facilities and have limited cash flow exposure to US generics markets. Biocon relies heavily on its operations in India and Malaysia for both biosimilar and generic products. Senores Pharmaceuticals is noted as having a local manufacturing operation specifically catering to the US generics market.